VISHC is pleased to invite you to a seminar on Engineering T Cells to Cure Human Disease.
EVENT DETAILS
đź“… Date & Time: Thursday, 20 March, 9 AM – 10 AM (Hanoi, GMT +7)
đź“Ť Location: VinUniversity, Peace Room I201
👨‍⚕️ Speaker: Doctor Michelle L. Hermiston – Vice Dean of Research in the College of Health Sciences at VinUniversity
đź”— Register ONLINE at: https://forms.gle/XGw13tpWj3VJrYzr8
WHAT TO EXPECT?
Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a revolutionary treatment modality in the field of immunotherapy. This therapy involves the genetic modification of a patient’s T cells to express CARs that specifically recognize antigens on the surface of the target cell, leading to targeted cytotoxicity and remission in patients who have failed conventional treatments. Building on the success in oncology, recent advancements have explored the potential of CAR-T cells in treating autoimmune diseases, such as lupus, by redirecting the immune response to restore self-tolerance. In this talk, we will discuss the dual application of CAR-T cell therapy in treating leukemia and lupus, highlighting the shared principles and distinct challenges in each disease context. Future research directions will be discussed, including optimizing CAR constructs, improving safety mechanisms, and understanding the long-term implications of CAR-T cell therapy.
ABOUT THE SPEAKER
Dr. Michelle L. Hermiston is the Vice Dean of Research in the College of Health Sciences at VinUniversity. Her research focuses on improving the outcomes for children, adolescents, and young adults with leukemia, lymphoma, and histiocytic disorders. She earned her B.S. at the University of Iowa and her MD and PhD degrees at Washington University School of Medicine and the Division of Biology and Biomedical Sciences. She completed a residency in general pediatrics and a fellowship in pediatric hematology and oncology at UCSF before joining the faculty in 2003. She developed and led the UCSF Pediatric Immunotherapy Program, and was Associate Director for education of the Helen Diller Comprehensive Cancer Center Global Cancer Program. She helped lead the development of the first-ever Ministry of Health approved training program in Pediatric Hematology-Oncology at the University of Medicine and Pharmacy in Ho Chi Minh. Nationally, she is one of the founding members of the North American Consortium for Histiocytoses (NACHO), currently chairs the Histiocyte Society Langerhans Cell Histiocytosis Committee, and is Vice Chair for the Children’s Oncology Group Non Hodgkin Lymphoma Steering Committee and chair of the NHL Biology committee where she participates in development and implementation of clinical trials.
đź“Ś For more information, contact us at shc@vinuni.edu.vn.
